First Time Loading...

Burning Rock Biotech Ltd
NASDAQ:BNR

Watchlist Manager
Burning Rock Biotech Ltd Logo
Burning Rock Biotech Ltd
NASDAQ:BNR
Watchlist
Price: 6.26 USD 4.68%
Updated: Jul 12, 2024
Have any thoughts about
Burning Rock Biotech Ltd?
Write Note

Intrinsic Value

Burning Rock Biotech Ltd. engages in the investment of medical fields. [ Read More ]

The intrinsic value of one BNR stock under the Base Case scenario is 20.39 USD. Compared to the current market price of 6.26 USD, Burning Rock Biotech Ltd is Undervalued by 69%.

Key Points:
BNR Intrinsic Value
Base Case
20.39 USD
Undervaluation 69%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Burning Rock Biotech Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling BNR stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Burning Rock Biotech Ltd

Current Assets 840.8m
Cash & Short-Term Investments 572.6m
Receivables 158.4m
Other Current Assets 109.8m
Non-Current Assets 144.1m
Long-Term Investments 249k
PP&E 134.2m
Intangibles 747k
Other Non-Current Assets 8.9m
Current Liabilities 255.4m
Accounts Payable 24.6m
Accrued Liabilities 102.1m
Other Current Liabilities 128.7m
Non-Current Liabilities 12.7m
Other Non-Current Liabilities 12.7m
Efficiency

Earnings Waterfall
Burning Rock Biotech Ltd

Revenue
520.5m CNY
Cost of Revenue
-170.4m CNY
Gross Profit
350.1m CNY
Operating Expenses
-956.8m CNY
Operating Income
-606.7m CNY
Other Expenses
16.7m CNY
Net Income
-590m CNY

Free Cash Flow Analysis
Burning Rock Biotech Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

BNR Profitability Score
Profitability Due Diligence

Burning Rock Biotech Ltd's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
ROIC is Increasing
Positive 3-Years Revenue Growth
25/100
Profitability
Score

Burning Rock Biotech Ltd's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

BNR Solvency Score
Solvency Due Diligence

Burning Rock Biotech Ltd's solvency score is 58/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
58/100
Solvency
Score

Burning Rock Biotech Ltd's solvency score is 58/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BNR Price Targets Summary
Burning Rock Biotech Ltd

Wall Street analysts forecast BNR stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BNR is 4.03 USD .

Lowest
Price Target
Not Available
Average
Price Target
4.03 USD
36% Downside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

BNR Price
Burning Rock Biotech Ltd

1M 1M
-20%
6M 6M
-33%
1Y 1Y
-72%
3Y 3Y
-98%
5Y 5Y
-97%
10Y 10Y
-97%
Annual Price Range
6.26
52w Low
5.52
52w High
22.1
Price Metrics
Average Annual Return -45.93%
Standard Deviation of Annual Returns 40.49%
Max Drawdown -99%
Shares Statistics
Market Capitalization 64.2m USD
Shares Outstanding 10 258 700
Percentage of Shares Shorted 0.45%

BNR Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Burning Rock Biotech Ltd Logo
Burning Rock Biotech Ltd

Country

China

Industry

Biotechnology

Market Cap

64.2m USD

Dividend Yield

0%

Description

Burning Rock Biotech Ltd. engages in the investment of medical fields. The company is headquartered in Guangzhou, Guangdong. The company went IPO on 2020-06-12. The firm operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The firm mainly conducts its businesses in the China market.

Contact

GUANGDONG
Guangzhou
No. 5 Xingdao Ring Road North,, International Bio Island
+8618501641666.0
http://www.brbiotech.com/

IPO

2020-06-12

Employees

938

Officers

Founder, Chairman & CEO
Mr. Yusheng Han
CFO, Compliance Officer & Director
Mr. Jinxiang Li
CTO & Director
Dr. Zhihong Zhang
Senior Advisor
Mr. Hao Liu

See Also

Discover More
What is the Intrinsic Value of one BNR stock?

The intrinsic value of one BNR stock under the Base Case scenario is 20.39 USD.

Is BNR stock undervalued or overvalued?

Compared to the current market price of 6.26 USD, Burning Rock Biotech Ltd is Undervalued by 69%.